DexCom Inc. DXCM and Abbott Laboratories ABT are likely to launch their first over-the-counter (OTC) continuous glucose monitors (CGMs) in the coming months of 2024. Dexcom’s Stelo and Abbott’s Lingo ...
Randomised controlled trial (RCT) assessed impact of two glucose monitoring systems on hypoglycaemia in people with type 1 diabetes EDINBURGH, Scotland, Jan. 30, 2018 /PRNewswire/ -- DexCom, Inc.
Hosted on MSN
Should You Buy DexCom Stock Before Oct. 31?
It's worth noting that DexCom is a leader in CGM, with some of the best devices on the market. The company's most important competitor, Abbott Laboratories, faced issues with its own FreeStyle Libre ...
Investors have a few questions as the company faces increasing competition. As the adage goes, two things in life are inevitable: death and taxes. Experienced growth investors might want to add a ...
Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes. If Vertex is successful, the CGM market could be ...
Dexcom's stock has been under a lot of selling pressure ever since Abbott won FDA approval for the FreeStyle Libre System in late 2017. The reason is that the Libre system does not need to be ...
FreeStyle Libre is a continuous glucose monitoring (CGM) system. It uses a sensor to read and check a person’s glucose levels. People with diabetes can use FreeStyle Libre to help manage the condition ...
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated ...
DexCom, Inc. (NASDAQ: DXCM) is a medical device company that pioneered the development of continuous glucose monitors (CGM) used by diabetics to more accurately track their blood glucose levels and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback